Comparative Pharmacology
Head-to-head clinical analysis: UNASYN versus UTIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNASYN versus UTIMOX.
UNASYN vs UTIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
For UTIMOX (amoxicillin/clavulanate), typical adult dose is 875 mg/125 mg orally every 12 hours or 500 mg/125 mg orally every 8 hours, depending on infection severity.
None Documented
None Documented
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 8-12 hours in severe impairment (CrCl <30 mL/min).
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Primarily renal (85-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic